MVASI Bevacizumab-awwb Syringes

Available from Edge Pharma
Product Menu
View Company Profile View all Products

Product Details

MVASI™ Bevacizumab-awwb, which was approved by the FDA in 2017, is now available in the United States. It is a new biosimilar to Avastin® that is widely used off-label in ophthalmology. Compliance and convenience are now possible with Edge Pharma's unit dose MVASI™ Bevacizumab-awwb syringes.

Rate and Review Edge Pharma - MVASI Bevacizumab-awwb Syringes

No reviews yet.

Let users know what you would have wanted to know about this company.

Write a Review
9/17/24- Pharm Mfg. - MR
Pharma_3:1_8.14.19
9/17/24- Pharm Mfg. - MR
Pharma_3:1_8.14.19